PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

FDA approves GSK measles vax

The U.S. FDA has approved Priorix, GlaxoSmithKline’s vaccine for measles, mumps and rubella (MMR) for use in patients aged 12 months and older.

While measles had once been considered eradicated from the United States thanks to vaccination efforts, the CDC has reported a resurgence in cases in the last few years. In 2019, 1,282 cases were reported, a staggering increase from 275 the year before.

While Priorix had been licensed in more than 100 countries worldwide, it is now available for the first time in the U.S. — adding another immunization option that providers can offer to parents. The new vaccine will compete with Merck’s M-M-R II vaccine, which won FDA approval back in 2008.

“We’re proud to make Priorix available in the U.S. for the first time, adding a choice for providers to help protect patients against these highly-contagious diseases and to further strengthen offerings in our pediatric vaccine portfolio,” said Judy Stewart, senior vice president and head of U.S. Vaccines at GSK.

The approval was supported by data from six clinical studies that included a total of 12,151 participants, 8,780 of whom were children. The studies confirmed that the vaccine-elicited immunity caused no serious adverse effects.

GSK also stated that Priorix is scheduled to be on the agenda for the June CDC Advisory Committee on Immunization Practices (ACIP) meeting to be considered for formal inclusion in the vaccine schedule and recommendations.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026